A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway

Aberrant activation of the classical complement pathway is the common underlying pathophysiology of orphan diseases such as bullous pemphigoid, antibody‐mediated rejection of organ transplants, cold agglutinin disease, and warm autoimmune hemolytic anemia. Therapeutic options for these complement‐me...

Full description

Saved in:
Bibliographic Details
Published in:Clin Pharmacol Ther
Main Authors: Bartko, Johann, Schoergenhofer, Christian, Schwameis, Michael, Firbas, Christa, Beliveau, Martin, Chang, Colin, Marier, Jean‐Francois, Nix, Darrell, Gilbert, James C., Panicker, Sandip, Jilma, Bernd
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2018
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6175298/
https://ncbi.nlm.nih.gov/pubmed/29737533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1111
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items